GRI Bio (GRI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
19 Dec, 2025Executive summary
Special Meeting scheduled for January 15, 2026, to be held virtually for increased participation and efficiency.
Stockholders of record as of December 19, 2025, are eligible to vote on the proposals.
Proxy materials and annual report are available online and by request.
Voting matters and shareholder proposals
Proposal 1 seeks approval to amend the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-2 and 1-for-30, with the exact ratio set by the board.
Proposal 2 requests approval to adjourn the meeting if more time is needed to solicit votes for Proposal 1.
Board recommends voting FOR both proposals.
Both proposals are considered routine, allowing brokers discretionary voting authority.
Stockholder proposals for the 2026 Annual Meeting must be submitted by March 16, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
Board retains discretion to set the reverse split ratio or abandon the split if not deemed necessary.
Board may consider market trends, stock price, and financial performance in its decision.
Board and executive officers have no substantial interests in the reverse split beyond their shareholdings.
Stockholders can communicate with the board via the Corporate Secretary.
Latest events from GRI Bio
- Lead candidate improved lung function and fibrosis biomarkers in IPF, with strong safety data.GRI
Corporate presentation16 Mar 2026 - Positive phase 2A IPF results and IND plans for lupus program signal strong pipeline momentum.GRI
Corporate Connect Webinar Series11 Feb 2026 - Strong cash position and positive clinical data support continued pipeline advancement.GRI
Q4 20254 Feb 2026 - Biopharma seeks up to $250M for immune therapies, advancing IPF and lupus programs amid high risk.GRI
Registration Filing30 Jan 2026 - Reverse stock split and adjournment proposals approved; results to be filed on Form 8-K.GRI
EGM 202615 Jan 2026 - Shareholders to vote on a reverse stock split to help maintain Nasdaq listing and flexibility.GRI
Proxy Filing29 Dec 2025 - Registering 1.58M shares for resale from warrants, with proceeds only if warrants are exercised.GRI
Registration Filing16 Dec 2025 - H.C. Wainwright & Co. is exclusive underwriter, earning 7% fees and warrants, with no future right of first refusal.GRI
Registration Filing10 Dec 2025 - Biopharma seeks $8.6M to advance IPF and autoimmune drug pipeline amid financial and Nasdaq risks.GRI
Registration Filing8 Dec 2025